Linked Life Data

21698834

Source:http://linkedlifedata.com/resource/pubmed/id/21698834

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-6-23
pubmed:abstractText
The UCSF clinical islet transplant program has evolved to utilize immunosuppressive strategies that do not rely on CNIs or other nephro- and beta-cell-toxic immunosuppressive agents. These novel strategies depend on lymphocyte-depleting induction immunotherapy and maintenance immunosuppression with novel agents that focus on co-stimulation and/or lymphocyte migration blockade. These drugs are well tolerated, frequently allow establishment of insulin independence after single islet infusions, and minimize allosensitization. Our early results suggest these regimens will be attractive immunosuppressive agents for future protocols in allogeneic islet transplantation as well as protocols utilizing stem-cell-derived beta cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0890-9016
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
235-43
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Clinical islet transplantation at the University of California, San Francisco.
pubmed:affiliation
Transplant Surgery, University of California San Francisco, San Francisco, CA, USA.
pubmed:publicationType
Journal Article